Monday 30 December 2019

INNOVATION - New biological medicine (approved by FDA in US) provides a new treatment option for patients with HER2-positive metastatic breast cancer who failed on multiple treatments. The medicine is approved on the basis of early (phase 2) clinical trial data and shows a complex safety profile with important side effects but is nevertheless deemed efficient and promising!